Vaccine Specific To Omicron To Be Developed Within Six Months, Says India's Serum Institute

Within six months, the Serum Institute of India is expected to create a new Omicron-specific vaccine.

In an interview with NDTV, institute chief Adar Poonawalla stated that the pharma giant is already working with US biotech company Novavax to develop a vaccine against Omicron sub-variant BA-52.

Poonawalla said the vaccine is important as a booster since Omicron is "not mild" and often manifests as a "serious cold."

It is not clear whether a separate Indian clinical trial is necessary for the vaccine to enter the market once it has been approved by national regulators.

Currently, Novavax is undergoing trials in Australia. By November-December, the company should be in a position to approach the US drug regulator," Mr Poonawalla said.
B5 and B2 variants of Omicron are currently spreading in Delhi, where authorities say they are more infectious than the base variant.

Comments Post Comment

Leave a Comment

Submit